Corrects company name to "Concentra" in bullet 3, corrects typographical error in bullet 5
** Shares of drug developer Acelyrin SLRN.O fall 12.7% to $2.30
** SLRN reiterates its planned merger with Alumis, says unsolicited buyout offer from Concentra Biosciences is not expected to result in superior proposal
** Concentra last month offered to buy Acelyrin for about $300 million, according to Reuters calculations
** SLRN early in February agreed to merge with Alumis in all-stock transaction
** Transaction is expected to close by Q2 2025
** SLRN stock has fallen 67.3% in past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。